|1.||Guilbaud, Nicolas: 7 articles (01/2016 - 12/2008)|
|2.||Bailly, Christian: 7 articles (01/2016 - 12/2008)|
|3.||Kruczynski, Anna: 5 articles (01/2016 - 12/2008)|
|4.||Annereau, Jean-Philippe: 3 articles (01/2016 - 12/2008)|
|5.||Brel, Viviane: 3 articles (12/2015 - 12/2008)|
|6.||Bailly, C: 3 articles (02/2014 - 10/2010)|
|7.||Vispé, Stéphane: 3 articles (12/2011 - 12/2008)|
|8.||Barret, Jean-Marc: 3 articles (02/2011 - 12/2008)|
|9.||Meignan, Samuel: 2 articles (01/2016 - 10/2014)|
|10.||Vandenberghe, Isabelle: 2 articles (01/2016 - 02/2011)|
02/01/2011 - "This study was aimed to define F14512 anticancer efficacy against tumor models and to investigate whether fluorophor-labeled polyamine probes could be used to identify tumors expressing a highly active PTS and that might be sensitive to F14512 treatments. "
11/01/2013 - "F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity."
11/01/2013 - "The polyamine moiety facilitates F14512 selective uptake by tumour cells via the polyamine transport system, a machinery overactivated in cancer cells. "
02/01/2011 - "We suggest that these probes could be used to identify tumors expressing a highly active PTS and guide the selection of patients that might be treated with F14512. "
02/01/2011 - "Eighteen tumor models were used to assess F14512 antitumor activity. "
12/01/2015 - "This trial demonstrated that F14512 can be safely administered to dogs with lymphoma resulting in strong therapeutic efficacy. "
12/01/2015 - "Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma."
12/01/2015 - "Twenty-three dogs with stage III-IV naturally occurring lymphomas were enrolled in the phase I dose-escalation trial, which consisted of three cycles of F14512 i.v. injections. "
12/01/2015 - "Because of the many similarities between human and dog lymphomas, we sought to determine the tolerance, efficacy, pharmacokinetic/pharmacodynamic (PK/PD) relationship of F14512 in this indication, and potential biomarkers that could be translated into human trials. "
12/01/2015 - "F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. "
10/01/2014 - "F14512 is a topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells via the Polyamine Transport System (PTS) and increases topoisomerase II poisoning. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|1.||Biological Markers (Surrogate Marker)
|3.||Type II DNA Topoisomerases (Topoisomerase II)
|5.||Etoposide (VP 16)
|6.||DNA (Deoxyribonucleic Acid)
|2.||Heterologous Transplantation (Xenotransplantation)